| Stakeholder type* . | Duplicate comments . | Unique comments . | ||||||
|---|---|---|---|---|---|---|---|---|
| Number of stakeholders addressing CED N = 5279** . | Of those stakeholders who expressed any opinion… . | Number of stakeholders addressing CED N = 1529 . | Of those stakeholders who expressed any opinion… . | |||||
| Oppose any coverage N (%) N = 5108 . | Favor CED N (%) N = 144 . | Favor full coverage N (%) N = 27 . | Oppose any coverage N (%) N = 479 . | Favor CED N (%) N = 571 . | Favor full coverage N (%) N = 479 . | |||
| Person living with Alzheimer’s disease (AD) | 1 | 1 (100.0%) | 0 (0.0%) | 0 (0%) | 4 | 0 (0.0%) | 1 (25.0%) | 3 (75.0%) |
| Family member or caregiver of person with AD | 79 | 65 (82.3%) | 7 (8.9%) | 7 (8.9%) | 226 | 36 (15.9%) | 55 (24.3%) | 135 (59.7%) |
| Person living with Down syndrome (DS) | 0 | – | – | – | 0 | – | – | – |
| Family member or caregiver of person with DS | 0 | – | – | – | 3 | 0 (0.0%) | 1 (33.3%) | 2 (66.7%) |
| AD patient advocacy organization | 3 | 0 (0.0%) | 1 (33.3%) | 2 (66.7%) | 21 | 1 (4.8%) | 2 (9.5%) | 18 (85.7%) |
| Other advocacy organization | 15 | 11 (73.3%) | 4 (26.7%) | 0 (0.0%) | 48 | 5 (10.4%) | 22 (45.8%) | 21 (43.8%) |
| Clinicians and other health care workers | 149 | 93 (62.4%) | 53 (35.6%) | 3 (2.0%) | 277 | 68 (24.5%) | 136 (49.1%) | 73 (26.4%) |
| Clinical society or organization | 3 | 3 (100.0%) | 0 (0.0%) | 0 (0.0%) | 17 | 2 (11.8%) | 9 (52.9%) | 6 (35.3%) |
| Pharmaceutical company or industry association | 1 | 1 (100.0%) | 0 (0.0%) | 0 (0.0%) | 14 | 0 (0.0%) | 5 (35.7%) | 9 (64.3%) |
| Insurer or other payer | 1 | 1 (100.0%) | 0 (0.0%) | 0 (0.0%) | 4 | 0 (0.0%) | 4 (100.0%) | 0 (0.0%) |
| Medicare beneficiary | 136 | 120 (88.2%) | 16 (11.8%) | 0 (0.0%) | 96 | 53 (55.2%) | 35 (36.5%) | 8 (8.3%) |
| Self-identified member of the general public or taxpayer | 50 | 48 (96.0%) | 1 (2.0%) | 1 (2.0%) | 48 | 19 (39.6%) | 21 (43.8%) | 8 (16.7%) |
| Academic (including researchers) | 64 | 58 (90.6%) | 6 (9.4%) | 0 (0.0%) | 102 | 21 (20.6%) | 66 (64.7%) | 15 (14.7%) |
| Other | 55 | 50 (90.9%) | 3 (5.5%) | 2 (3.6%) | 59 | 11 (18.6%) | 22 (37.3%) | 26 (44.1%) |
| Not specified/not sure | 4722 | 4657 (98.6%) | 53 (1.1%) | 12 (0.3%) | 610 | 263 (43.1%) | 192 (31.5%) | 155 (25.4%) |
| Stakeholder type* . | Duplicate comments . | Unique comments . | ||||||
|---|---|---|---|---|---|---|---|---|
| Number of stakeholders addressing CED N = 5279** . | Of those stakeholders who expressed any opinion… . | Number of stakeholders addressing CED N = 1529 . | Of those stakeholders who expressed any opinion… . | |||||
| Oppose any coverage N (%) N = 5108 . | Favor CED N (%) N = 144 . | Favor full coverage N (%) N = 27 . | Oppose any coverage N (%) N = 479 . | Favor CED N (%) N = 571 . | Favor full coverage N (%) N = 479 . | |||
| Person living with Alzheimer’s disease (AD) | 1 | 1 (100.0%) | 0 (0.0%) | 0 (0%) | 4 | 0 (0.0%) | 1 (25.0%) | 3 (75.0%) |
| Family member or caregiver of person with AD | 79 | 65 (82.3%) | 7 (8.9%) | 7 (8.9%) | 226 | 36 (15.9%) | 55 (24.3%) | 135 (59.7%) |
| Person living with Down syndrome (DS) | 0 | – | – | – | 0 | – | – | – |
| Family member or caregiver of person with DS | 0 | – | – | – | 3 | 0 (0.0%) | 1 (33.3%) | 2 (66.7%) |
| AD patient advocacy organization | 3 | 0 (0.0%) | 1 (33.3%) | 2 (66.7%) | 21 | 1 (4.8%) | 2 (9.5%) | 18 (85.7%) |
| Other advocacy organization | 15 | 11 (73.3%) | 4 (26.7%) | 0 (0.0%) | 48 | 5 (10.4%) | 22 (45.8%) | 21 (43.8%) |
| Clinicians and other health care workers | 149 | 93 (62.4%) | 53 (35.6%) | 3 (2.0%) | 277 | 68 (24.5%) | 136 (49.1%) | 73 (26.4%) |
| Clinical society or organization | 3 | 3 (100.0%) | 0 (0.0%) | 0 (0.0%) | 17 | 2 (11.8%) | 9 (52.9%) | 6 (35.3%) |
| Pharmaceutical company or industry association | 1 | 1 (100.0%) | 0 (0.0%) | 0 (0.0%) | 14 | 0 (0.0%) | 5 (35.7%) | 9 (64.3%) |
| Insurer or other payer | 1 | 1 (100.0%) | 0 (0.0%) | 0 (0.0%) | 4 | 0 (0.0%) | 4 (100.0%) | 0 (0.0%) |
| Medicare beneficiary | 136 | 120 (88.2%) | 16 (11.8%) | 0 (0.0%) | 96 | 53 (55.2%) | 35 (36.5%) | 8 (8.3%) |
| Self-identified member of the general public or taxpayer | 50 | 48 (96.0%) | 1 (2.0%) | 1 (2.0%) | 48 | 19 (39.6%) | 21 (43.8%) | 8 (16.7%) |
| Academic (including researchers) | 64 | 58 (90.6%) | 6 (9.4%) | 0 (0.0%) | 102 | 21 (20.6%) | 66 (64.7%) | 15 (14.7%) |
| Other | 55 | 50 (90.9%) | 3 (5.5%) | 2 (3.6%) | 59 | 11 (18.6%) | 22 (37.3%) | 26 (44.1%) |
| Not specified/not sure | 4722 | 4657 (98.6%) | 53 (1.1%) | 12 (0.3%) | 610 | 263 (43.1%) | 192 (31.5%) | 155 (25.4%) |
*Commentors could be identified as belonging to more than 1 stakeholder group.
**Many commenters expressed no opinion on CED.
| Stakeholder type* . | Duplicate comments . | Unique comments . | ||||||
|---|---|---|---|---|---|---|---|---|
| Number of stakeholders addressing CED N = 5279** . | Of those stakeholders who expressed any opinion… . | Number of stakeholders addressing CED N = 1529 . | Of those stakeholders who expressed any opinion… . | |||||
| Oppose any coverage N (%) N = 5108 . | Favor CED N (%) N = 144 . | Favor full coverage N (%) N = 27 . | Oppose any coverage N (%) N = 479 . | Favor CED N (%) N = 571 . | Favor full coverage N (%) N = 479 . | |||
| Person living with Alzheimer’s disease (AD) | 1 | 1 (100.0%) | 0 (0.0%) | 0 (0%) | 4 | 0 (0.0%) | 1 (25.0%) | 3 (75.0%) |
| Family member or caregiver of person with AD | 79 | 65 (82.3%) | 7 (8.9%) | 7 (8.9%) | 226 | 36 (15.9%) | 55 (24.3%) | 135 (59.7%) |
| Person living with Down syndrome (DS) | 0 | – | – | – | 0 | – | – | – |
| Family member or caregiver of person with DS | 0 | – | – | – | 3 | 0 (0.0%) | 1 (33.3%) | 2 (66.7%) |
| AD patient advocacy organization | 3 | 0 (0.0%) | 1 (33.3%) | 2 (66.7%) | 21 | 1 (4.8%) | 2 (9.5%) | 18 (85.7%) |
| Other advocacy organization | 15 | 11 (73.3%) | 4 (26.7%) | 0 (0.0%) | 48 | 5 (10.4%) | 22 (45.8%) | 21 (43.8%) |
| Clinicians and other health care workers | 149 | 93 (62.4%) | 53 (35.6%) | 3 (2.0%) | 277 | 68 (24.5%) | 136 (49.1%) | 73 (26.4%) |
| Clinical society or organization | 3 | 3 (100.0%) | 0 (0.0%) | 0 (0.0%) | 17 | 2 (11.8%) | 9 (52.9%) | 6 (35.3%) |
| Pharmaceutical company or industry association | 1 | 1 (100.0%) | 0 (0.0%) | 0 (0.0%) | 14 | 0 (0.0%) | 5 (35.7%) | 9 (64.3%) |
| Insurer or other payer | 1 | 1 (100.0%) | 0 (0.0%) | 0 (0.0%) | 4 | 0 (0.0%) | 4 (100.0%) | 0 (0.0%) |
| Medicare beneficiary | 136 | 120 (88.2%) | 16 (11.8%) | 0 (0.0%) | 96 | 53 (55.2%) | 35 (36.5%) | 8 (8.3%) |
| Self-identified member of the general public or taxpayer | 50 | 48 (96.0%) | 1 (2.0%) | 1 (2.0%) | 48 | 19 (39.6%) | 21 (43.8%) | 8 (16.7%) |
| Academic (including researchers) | 64 | 58 (90.6%) | 6 (9.4%) | 0 (0.0%) | 102 | 21 (20.6%) | 66 (64.7%) | 15 (14.7%) |
| Other | 55 | 50 (90.9%) | 3 (5.5%) | 2 (3.6%) | 59 | 11 (18.6%) | 22 (37.3%) | 26 (44.1%) |
| Not specified/not sure | 4722 | 4657 (98.6%) | 53 (1.1%) | 12 (0.3%) | 610 | 263 (43.1%) | 192 (31.5%) | 155 (25.4%) |
| Stakeholder type* . | Duplicate comments . | Unique comments . | ||||||
|---|---|---|---|---|---|---|---|---|
| Number of stakeholders addressing CED N = 5279** . | Of those stakeholders who expressed any opinion… . | Number of stakeholders addressing CED N = 1529 . | Of those stakeholders who expressed any opinion… . | |||||
| Oppose any coverage N (%) N = 5108 . | Favor CED N (%) N = 144 . | Favor full coverage N (%) N = 27 . | Oppose any coverage N (%) N = 479 . | Favor CED N (%) N = 571 . | Favor full coverage N (%) N = 479 . | |||
| Person living with Alzheimer’s disease (AD) | 1 | 1 (100.0%) | 0 (0.0%) | 0 (0%) | 4 | 0 (0.0%) | 1 (25.0%) | 3 (75.0%) |
| Family member or caregiver of person with AD | 79 | 65 (82.3%) | 7 (8.9%) | 7 (8.9%) | 226 | 36 (15.9%) | 55 (24.3%) | 135 (59.7%) |
| Person living with Down syndrome (DS) | 0 | – | – | – | 0 | – | – | – |
| Family member or caregiver of person with DS | 0 | – | – | – | 3 | 0 (0.0%) | 1 (33.3%) | 2 (66.7%) |
| AD patient advocacy organization | 3 | 0 (0.0%) | 1 (33.3%) | 2 (66.7%) | 21 | 1 (4.8%) | 2 (9.5%) | 18 (85.7%) |
| Other advocacy organization | 15 | 11 (73.3%) | 4 (26.7%) | 0 (0.0%) | 48 | 5 (10.4%) | 22 (45.8%) | 21 (43.8%) |
| Clinicians and other health care workers | 149 | 93 (62.4%) | 53 (35.6%) | 3 (2.0%) | 277 | 68 (24.5%) | 136 (49.1%) | 73 (26.4%) |
| Clinical society or organization | 3 | 3 (100.0%) | 0 (0.0%) | 0 (0.0%) | 17 | 2 (11.8%) | 9 (52.9%) | 6 (35.3%) |
| Pharmaceutical company or industry association | 1 | 1 (100.0%) | 0 (0.0%) | 0 (0.0%) | 14 | 0 (0.0%) | 5 (35.7%) | 9 (64.3%) |
| Insurer or other payer | 1 | 1 (100.0%) | 0 (0.0%) | 0 (0.0%) | 4 | 0 (0.0%) | 4 (100.0%) | 0 (0.0%) |
| Medicare beneficiary | 136 | 120 (88.2%) | 16 (11.8%) | 0 (0.0%) | 96 | 53 (55.2%) | 35 (36.5%) | 8 (8.3%) |
| Self-identified member of the general public or taxpayer | 50 | 48 (96.0%) | 1 (2.0%) | 1 (2.0%) | 48 | 19 (39.6%) | 21 (43.8%) | 8 (16.7%) |
| Academic (including researchers) | 64 | 58 (90.6%) | 6 (9.4%) | 0 (0.0%) | 102 | 21 (20.6%) | 66 (64.7%) | 15 (14.7%) |
| Other | 55 | 50 (90.9%) | 3 (5.5%) | 2 (3.6%) | 59 | 11 (18.6%) | 22 (37.3%) | 26 (44.1%) |
| Not specified/not sure | 4722 | 4657 (98.6%) | 53 (1.1%) | 12 (0.3%) | 610 | 263 (43.1%) | 192 (31.5%) | 155 (25.4%) |
*Commentors could be identified as belonging to more than 1 stakeholder group.
**Many commenters expressed no opinion on CED.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
